Wellgistics converts $1,300,000 and $4,019,859 debt to equity

Wellgistics Health (WGRX) reported capital-structure changes.

Rhea-AI Filing Summary

Wellgistics Health (WGRX) reported capital-structure changes. Holders exercised warrants at an exercise price of $0.70 per share, resulting in the issuance of 3,111,429 shares of common stock.

The company also entered two debt conversion agreements on October 30, 2025. It converted $1,300,000 of indebtedness into 1,857,143 shares at $0.70 per share, and converted $4,019,859 of indebtedness into 5,742,656 shares at $0.70 per share, in each case in full satisfaction of the underlying obligations.

Insights

Capital structure analyst

Equity issuance via warrant exercises and debt-for-equity swaps.

Wellgistics Health issued new shares through warrant exercises at $0.70 per share, adding 3,111,429 shares. Separately, the company executed two debt-for-equity conversions dated October 30, 2025, swapping $1,300,000 for 1,857,143 shares and $4,019,859 for 5,742,656 shares, each at $0.70.

These actions reduce outstanding debt while increasing the share count. Actual impact depends on the company’s existing float and future trading dynamics. Proceeds treatment for the warrant exercises is not detailed in the excerpt.

Subsequent filings may provide updated share counts and any effects on per‑share metrics following the issuances and conversions.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Wellgistics Health (WGRX) announce regarding warrant exercises?

Holders exercised warrants at an exercise price of $0.70 per share, resulting in the issuance of 3,111,429 common shares.

How much debt did WGRX convert to equity on October 30, 2025?

The company converted $1,300,000 and $4,019,859 of indebtedness into common stock at $0.70 per share.

How many shares were issued in Wellgistics’ debt conversions?

The conversions resulted in 1,857,143 shares and 5,742,656 shares, respectively, each priced at $0.70 per share.

What is the trading symbol and exchange for Wellgistics Health?

The common stock trades under WGRX on The Nasdaq Capital Market LLC.

Were the converted debts fully satisfied by the share issuances?

Yes. Each conversion was in full satisfaction of the respective obligations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/30/2025 - 05:19 PM EDT Learn about SEC filing dates

false 0002030763 0002030763 2025-10-24 2025-10-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 24, 2025

WELLGISTICS HEALTH, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-42530		93-3264234
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3000 Bayport Drive

Suite 950

Tampa, FL 33607

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (844) 203-6092

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

	☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		WGRX		The Nasdaq Capital Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

Exercise of Warrants

On October 24, 2025, certain holders of warrants exercised warrants at an exercise price of $0.70 per share of common stock resulting in the issuance of 3,111,429 shares of the Company’s common stock in the aggregate to such holders.

Integra Health Inc. Debt Conversion Agreement

On October 30, 2025, the Company entered into a Debt Conversion Agreement (the “Integra Health DCA”), by and among the Company, Integra Health Inc., a Florida corporation (“Integra Health”), and WoodSage LLC, a Florida limited liability company and a wholly-owned subsidiary of the Company (“WoodSage”). The Integra Health DCA addressed the conversion of indebtedness in the amount of $1,3000,000 due pursuant to a promissory note issued by WoodSage in favor of Integra Health, dated as of August 22, 2023 (the “Note”). Under the Integra Health DCA, the indebtedness in the among of $1,300,000 was converted into shares of the Corporation’s common stock at a price per share of $0.70 for an aggregate number of shares of 1,857,143 in full satisfaction of the obligations of WoodSage outstanding under the Note.

Integra Pharma Solutions, LLC Debt Conversion Agreement

On October 30, 2025, the Company entered into a Debt Conversion Agreement (the “Integra Pharma DCA”), by and among, the Company, Integra Pharma Solutions, LLC, a Florida limited liability company (“Integra Pharma”), and WoodSage. The Integra Pharma DCA addressed the conversion of indebtedness in the amount of $4,019,859 due to Integra Pharma by WoodSage in connection with the Sale of Goods Agreement by and between Integra Pharma and WoodSage, dated as of August 2023 (the “Sale Agreement”). Under the Integra Pharma DCA, the indebtedness in the among of $4,019,859 was converted into shares of the Corporation’s common stock at a price per share of $0.70 for an aggregate number of shares of 5,742,656 143 in full satisfaction of the obligations of WoodSage outstanding under the Sale Agreement.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following exhibits are filed as part of, or incorporated by reference into, this Report.

Exhibit No.		Description
104*		Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 30, 2025	WELLGISTICS HEALTH, INC.
	By:	/s/ Prashant Patel
		Prashant Patel, President